日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

您現在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




主站蜘蛛池模板: 一级片精品 | 欧美激情性做爰免费视频 | 亚洲成人一区二区 | 国产精品12| 日韩黄色免费 | 四虎在线永久 | 久久99国产综合精品免费 | 99精品视频在线观看 | 天堂网av手机版 | 天天色影院 | 国产三级在线 | 欧美色图一区 | 欧美日韩亚洲系列 | 黄色蜜桃视频 | 精品欧美乱码久久久久久 | 男人的伸进里面免费网站 | 2017亚洲天堂 | 91精品网 | 色综合网址 | 国产欧美精品一区二区三区 | 国产一区二区精品在线 | 久久亚洲天堂 | 纯爱无遮挡h肉动漫在线播放 | 欧美videos另类精品 | 久久久888| 成年人免费网站在线观看 | 天堂中文字幕在线 | 亚洲三级中文字幕 | av网站免费在线观看 | 网站在线播放 | 欧美视频免费在线观看 | 91九色网站 | 密桃av| 超碰在线免费播放 | 中文天堂在线资源 | 先锋资源中文字幕 | 国产精品自在线 | 日本免费三片在线播放 | 欧美精品日韩精品 | 国产精品一二三四五区 | 国产主播av |